|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500100488 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-10 09:37:36 |
|
注册时间: Date of Registration: |
2025-04-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国帕金森病患者基因型与疾病进展关联分析 |
|
Public title: |
Association Analysis Between Genotypes and Disease Progression in Parkinson's Disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国帕金森病患者基因型与疾病进展关联分析 |
|
Scientific title: |
Association Analysis Between Genotypes and Disease Progression in Parkinson's Disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙一忞 |
研究负责人: |
孙一忞 |
|
Applicant: |
Yimin Sun |
Study leader: |
Yimin Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1708 1859 |
研究负责人电话: Study leader's telephone: |
+86 13917081859 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ys2504@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
B0636@huashan.org.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区乌鲁木齐中路12号 |
研究负责人通讯地址: |
乌鲁木齐中路12号 |
|
Applicant address: |
No. 12, Urumqi Middle Road, Jing'an District, Shanghai |
Study leader's address: |
No. 12, Urumqi Middle Road, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属华山医院 |
||
|
Applicant's institution: |
Huashan Hospital affiliated to Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属华山医院 |
||
|
Affiliation of the Leader: |
Huashan Hospital affiliated to Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)临审第(013)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属华山医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board Huashan Hospital Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-17 00:00:00 |
||
|
伦理委员会联系人: |
全菁 |
||
|
Contact Name of the ethic committee: |
Quan Jing |
||
|
伦理委员会联系地址: |
上海市静安区乌鲁木齐中路12号 |
||
|
Contact Address of the ethic committee: |
No. 12, Urumqi Middle Road, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 52888921 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
quanjing1975@163.com |
|
研究实施负责(组长)单位: |
复旦大学附属华山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Huashan Hospital, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区乌鲁木齐中路12号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 12, Urumqi Middle Road, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||
|
Target disease: |
Parkinson's Disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
探究早发型帕金森病、晚发散发型帕金森病和晚发有家族史的帕金森病患者的基因型分布情况以及不同基因型的帕金森病疾病进展异质性,为今后中国帕金森病人群基因筛查、早期干预及个体化治疗提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the genotype distribution of patients with early-onset Parkinson's disease, late-onset sporadic Parkinson's disease and late-onset Parkinson's disease with family history, as well as the heterogeneity of Parkinson's disease progression among different genotypes, so as to provide a basis for genetic screening, early intervention and individualized treatment of Parkinson's disease in China in the future. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)临床确诊帕金森病:2014年6月至2015年12月根据英国伦敦帕金森协会脑库(United Kingdom Parkinson's Disease Society Brain Bank)制定的诊断标准, 2015年12月至2024 年10月根据运动障碍协会(Movement Disorder Society, MDS)制定的诊断标准进行PD诊断。年龄在18-90岁之间,性别不限。所有诊断均由至少三名神经内科运动障碍亚专科专家共同确认; (2)已行帕金森病相关二代测序及多重连接依赖式探针扩增检测。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Clinically diagnosed Parkinson's disease: from June 2014 to December 2015, according to the diagnostic criteria formulated by the United Kingdom Parkinson's Disease Society Brain Bank, and from December 2015 to October 2024, according to the Movement Disorder Society, MDS). Age between 18-90 years, gender is not limited. All diagnoses were confirmed by at least three neurology movement disorder subspecialty specialists; (2) Parkinson's disease-related next-generation sequencing and multiplex ligation-dependent probe amplification detection have been performed. |
||||||||||||||||||||||
|
排除标准: |
(1)已行脑深部电刺激手术的帕金森病患者; (2)帕金森病叠加综合征; (3)其他继发性帕金森病; (4) 合并其他中枢或者周围神经系统疾病者; (5)合并其他严重内科系统疾病,无法耐受评估者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients with Parkinson's disease who have undergone deep brain stimulation surgery; (2) Parkinson's disease superposition syndrome; (3) other secondary Parkinson's disease; (4) Those with other central or peripheral nervous system diseases; (5) Patients with other serious internal medicine system diseases that cannot tolerate the evaluation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-03-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-04-15 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据均记录在帕金森病及其高危人群临床信息和生物样本库中 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data were recorded in the Clinical Information and biobank of Parkinson's disease and its high-risk population |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |